Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ, Braybrooke JP, Levitt NC, O'Byrne K, Christodoulos K, Han C, Talbot DC, Ganesan TS, Harris AL. Propper DJ, et al. Among authors: han c. Br J Cancer. 2000 Jun;82(11):1759-63. doi: 10.1054/bjoc.2000.1141. Br J Cancer. 2000. PMID: 10839287 Free PMC article. Clinical Trial.
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.
Madhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P, Turner A, Balkwill F, Hoare S, Harris AL. Madhusudan S, et al. Among authors: han c. Br J Cancer. 2003 Oct 20;89(8):1418-22. doi: 10.1038/sj.bjc.6601321. Br J Cancer. 2003. PMID: 14562010 Free PMC article. Clinical Trial.
Phase II study of liarozole in advanced non-small cell lung cancer.
O'Byrne KJ, Han C, Mitchell K, Lane D, Carmichael J, Harris AL, Talbot DC. O'Byrne KJ, et al. Among authors: han c. Eur J Cancer. 1998 Aug;34(9):1463-6. doi: 10.1016/s0959-8049(98)00144-0. Eur J Cancer. 1998. PMID: 9849433 Clinical Trial.
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL. Braybrooke JP, et al. Among authors: han c. Clin Cancer Res. 2000 Dec;6(12):4697-704. Clin Cancer Res. 2000. PMID: 11156222 Clinical Trial.
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
Muthuramalingam SR, Braybrooke JP, Blann AD, Madhusudan S, Wilner S, Jenkins A, Han C, Kaur K, Perren T, Ganesan TS. Muthuramalingam SR, et al. Among authors: han c. Eur J Gynaecol Oncol. 2011;32(3):253-8. Eur J Gynaecol Oncol. 2011. PMID: 21797111 Clinical Trial.
9,401 results